Sponsored
Experts consider what happens when artificial intelligence (A) tools multiply faster than organizations can connect them.
Shankar Narayanan
Advertisement
Articles by Shankar Narayanan
Sponsored
Zoe Lazarra, Claudia Ciciliano, and Shankar Narayanan assess where artificial intelligence (AI) is already proving its value in pharma commercialization and where to go next.
Sponsored
A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities
2
Where AI Can Strengthen Clinical Research, and Where Patient Input is More Important
3
The US Drug-Pricing Reset: Competing on Net Value
4
Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.
5